Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Non-Current Liabilities: 2018-2025

  • Dr Reddys Laboratories' Total Non-Current Liabilities rose 125.76% to $298.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $298.0 million, marking a year-over-year increase of 125.76%. This contributed to the annual value of $298.0 million for FY2025, which is 125.76% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Total Non-Current Liabilities stood at $298.0 million for Q1 2025, which was up 125.76% from $132.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' 5-year Total Non-Current Liabilities high stood at $298.0 million for Q1 2025, and its period low was $61.0 million during Q1 2023.
  • For the 3-year period, Dr Reddys Laboratories' Total Non-Current Liabilities averaged around $163.7 million, with its median value being $132.0 million (2024).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 44.04% in 2023, then skyrocketed by 125.76% in 2025.
  • Dr Reddys Laboratories' Total Non-Current Liabilities (Quarterly) stood at $124.0 million in 2021, then fell by 12.10% to $109.0 million in 2022, then slumped by 44.04% to $61.0 million in 2023, then soared by 116.39% to $132.0 million in 2024, then skyrocketed by 125.76% to $298.0 million in 2025.
  • Its last three reported values are $298.0 million in Q1 2025, $132.0 million for Q1 2024, and $61.0 million during Q1 2023.